Medical research

'Unsung' cells double the benefits of a new osteoporosis drug

Experiments in mice with a bone disorder similar to that in women after menopause show that a scientifically overlooked group of cells are likely crucial to the process of bone loss caused by the disorder, according to Johns ...

Medical research

Revealing a novel mode of action for an osteoporosis drug

(Medical Xpress)—Raloxifene is a U.S. Food and Drug Administration (FDA)-approved treatment for decreasing fracture risk in osteoporosis. While raloxifene is as effective at reducing fracture risk as other current treatments, ...

Overweight & Obesity

Bone loss persists two years after weight loss surgery

A new study shows that for at least two years after bariatric surgery, patients continue to lose bone, even after their weight stabilizes. The results—in patients undergoing gastric bypass, the most common type of weight ...

Diseases, Conditions, Syndromes

Romosozumab increases bone mineral density post-menopause

(HealthDay)—Romosozumab seems safe and effective for increasing bone mineral density in postmenopausal women with low bone mineral density, according to a study published online Jan. 1 in the New England Journal of Medicine.

Medical research

Bone loss associated with increased production of ROS

Bone is constantly being broken down and remodeled. Osteoporosis results when bone resorption outpaces bone regeneration. Production of reactive oxygen species, a form of oxidative stress, has been predicted to promote bone ...

Medical research

Mechanical stimuli control bone development

Researchers from ETH Zurich have successfully demonstrated, for the first time in vivo, how bone tissue responds to local mechanical stimuli that control bone formation. The study reveals how important it is to stimulate ...

page 5 from 7